Welcome to our dedicated page for Mineralys Therapeutics SEC filings (Ticker: MLYS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Mineralys Therapeutics, Inc. filings document the public-company disclosures of a biopharmaceutical issuer developing lorundrostat for hypertension and related comorbidities driven by dysregulated aldosterone. Form 8-K reports cover quarterly and annual financial results, corporate updates, Regulation FD disclosures, FDA acceptance of the lorundrostat New Drug Application, and clinical results from the Explore-OSA exploratory trial.
The filing record also includes proxy materials for annual meeting voting and stockholder procedures, along with material-event disclosures for capital-structure matters. These include common stock arrangements under an ATM Equity Offering Sales Agreement, registration-statement references, material agreements, and shareholder voting matters.
Mineralys Therapeutics, Inc. Chief Medical Officer David Malcom Rodman exercised stock options for 2,170 shares of common stock at $16.00 per share and then sold 2,170 shares in an open-market transaction at $27.38 per share.
These transactions were made under a pre-arranged Rule 10b5-1 trading plan adopted on October 6, 2025. Following the sale, he directly holds 76,140 shares of Mineralys Therapeutics common stock.
Jon Congleton reported Rule 144 transactions in Mineralys Therapeutics common stock, including sales of 16,236 shares on 01/12/2026 for $529,639.51 and 75,000 shares on 03/31/2026 for $1,970,520.69. The filing also shows a vesting of 15,730 restricted share units on 04/10/2026 granted under the issuer's equity compensation plan.
Mineralys Therapeutics, Inc. affiliate submitted a Form 144 notice reporting proposed sales of 14,058 shares of common stock for $373,086.81 to occur on 04/13/2026 via a broker-assisted cashless exercise. The filing also lists multiple open-market dispositions by David Rodman totaling repeated small sales across January–April 2026, including a 14,058-share sale on 03/13/2026 for $369,225.07.
Mineralys Therapeutics, Inc. filing under Rule 144 discloses an intended sale of 2,170 shares of Common Stock on 04/09/2026 tied to an exercise of employee stock options executed as a broker-assisted cashless exercise. The filing also lists multiple recent open-market dispositions by David Rodman, including sales on 01/14/2026 (11,367 shares for $370,645.39) and 03/13/2026 (14,058 shares for $369,225.07).
The notice is a typical Rule 144 transaction report describing specific shares to be sold and a sequence of recent sales; cash‑flow treatment and remaining holdings are not stated in the excerpt.
Mineralys Therapeutics, Inc. will hold its 2026 annual stockholder meeting as a virtual-only webcast on May 21, 2026 at 1:30 p.m. Eastern Time. Stockholders will vote on electing three Class III directors through 2029 and ratifying Ernst & Young LLP as independent auditor for 2026.
Holders of 82,451,950 common shares as of March 25, 2026 are entitled to one vote per share and may vote online, by telephone, by mail, or during the webcast. The proxy details board structure, committee responsibilities, major stockholders, and 2025 compensation for key executives, including salary, bonuses, and stock option awards.
Mineralys Therapeutics, Inc. Chief Executive Officer Jon Congleton reported open-market sales of a total of 75,000 shares of the company’s Common Stock on March 31, 2026. The transactions were executed at weighted-average prices of $25.5006, $26.5385, and $27.0511 per share across multiple trades. These sales were carried out under a pre-arranged Rule 10b5-1 trading plan adopted on December 30, 2025. Following the transactions, Congleton directly holds 705,051 shares of Mineralys Therapeutics Common Stock.
Mineralys Therapeutics director Daphne Karydas reported an option exercise and share sale. She exercised stock options to acquire 3,000 shares of common stock at $12.02 per share, then sold 3,000 common shares in an open-market transaction at $25.00 per share.
After these transactions, she directly holds 6,200 shares of common stock and 41,000 stock options. The filing notes that these trades were carried out under a pre-arranged Rule 10b5-1 trading plan adopted on December 30, 2025.
Mineralys Therapeutics reported a proposed sale of 3,000 shares of Common Stock under a Form 144 related to an exercise of employee stock options on 03/31/2026. The transaction is listed as a broker assisted cashless exercise through Merrill Lynch with aggregate value shown as $75,000.00.
Mineralys Therapeutics files a Form 144 reporting proposed sales of 75,000 shares of Common Stock. The filing lists an aggregate offering price of $1,970,520.69 and notes total shares outstanding of 82,399,478 as of 03/31/2026. It also discloses recent vesting of restricted share units (63,665 and 11,335 shares) and a related sale by Jon Congleton of 16,236 shares on 01/12/2026 for $529,639.51.